- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14:26 | Wall Street Rallies Behind Lexeo Therapeutics (LXEO)'s Gene Therapy Pipeline | 2 | Insider Monkey | ||
| 17.12. | Raymond James initiates Lexeo Therapeutics stock with Strong Buy rating | 2 | Investing.com | ||
| 10.12. | Lexeo Therapeutics stock holds Overweight rating as Cantor sees PKP2-ACM potential | 1 | Investing.com | ||
| LEXEO THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 10.12. | Oppenheimer reiterates Outperform rating on Lexeo Therapeutics stock | 1 | Investing.com | ||
| 01.12. | Lexeo Therapeutics stock undervalued, Cantor Fitzgerald reiterates $19 target | 2 | Investing.com | ||
| 01.12. | Cantor Fitzgerald stuft Lexeo Therapeutics als unterbewertet ein und bestätigt Kursziel von 19 $ | 1 | Investing.com Deutsch | ||
| 05.11. | Lexeo Therapeutics GAAP EPS of -$0.33 beats by $0.24 | 3 | Seeking Alpha | ||
| 05.11. | Lexeo Therapeutics Reports Third Quarter 2025 Financial Results and Operational Highlights | 276 | GlobeNewswire (Europe) | FDA open to pooling data from ongoing Phase I/II studies of LX2006 with data from pivotal trial, and to earlier co-primary endpoint assessment, to support a Biologics License Application FDA approved... ► Artikel lesen | |
| 05.11. | Lexeo Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 05.11. | Lexeo Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 05.11. | Lexeo Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 20.10. | Lexeo Therapeutics raises $153.8 million in public offering | 4 | Investing.com | ||
| 20.10. | Lexeo Therapeutics Announces Closing of Public Offering and Concurrent Private Placement and Exercise in Full of the Underwriters' Option to Purchase Additional Shares in the Public Offering | 1 | GlobeNewswire (USA) | ||
| 17.10. | Lexeo Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 17.10. | Stifel lowers Lexeo Therapeutics stock price target to $18 on offering | 5 | Investing.com | ||
| 17.10. | Lexeo Therapeutics Announces FDA Support for Accelerated Approval Pathway, Positive Interim Data for Gene Therapy LX2006 | 4 | Insider Monkey | ||
| 17.10. | Lexeo Therapeutics prices $135M public offering and private placement | 2 | Seeking Alpha | ||
| 17.10. | Lexeo Therapeutics platziert Aktien und Optionsscheine im Wert von 135 Millionen US-Dollar | 1 | Investing.com Deutsch | ||
| 17.10. | Lexeo Therapeutics prices $135 million public offering and placement | 2 | Investing.com | ||
| 17.10. | Lexeo Therapeutics Announces Pricing of Public Offering and Concurrent Private Placement | 1 | GlobeNewswire (USA) |
1 2 3 Weiter >>
49 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SANGAMO THERAPEUTICS | 0,324 | -6,92 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease | STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA)... ► Artikel lesen | |
| T2 BIOSYSTEMS | 0,250 | 0,00 % | NSE/A - T2 Biosystems, Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | ||
| AVID BIOSERVICES | 12,100 | 0,00 % | Avid Bioservices appoints Dave Stewart as Chief Technology and Transformation Officer | The newly created role marks a major step in CEO Kenneth Bilenberg's vision to scale Avid for its next chapter of growth.
TUSTIN, Calif., Nov. 10, 2025 /PRNewswire/... ► Artikel lesen | |
| PROTALIX BIOTHERAPEUTICS | 1,480 | -0,67 % | EQS-News: Secarna Pharmaceuticals GmbH & Co. KG: Secarna Pharmaceuticals and Protalix Biotherapeutics Enter into Collaboration and Option Agreement | EQS-News: Secarna Pharmaceuticals GmbH & Co. KG
/ Key word(s): Agreement
Secarna Pharmaceuticals and Protalix Biotherapeutics Enter into Collaboration and Option Agreement
17.12.2025... ► Artikel lesen | |
| REPLIMUNE | 8,050 | 0,00 % | Replimune, Inc.: Replimune Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma | WOBURN, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced... ► Artikel lesen | |
| ENZO BIOCHEM | 0,388 | 0,00 % | Battery Ventures Completes Take-Private of Enzo Biochem | Apter joins as CEO to support the next stage of growth for the life-science reagents platform
BOSTON--(BUSINESS WIRE)--Battery Ventures, a global, technology-focused investment firm, announced the... ► Artikel lesen | |
| QUANTERIX | 6,460 | -2,42 % | Quanterix Corporation: Quanterix Announces Landmark Nature Study Redefining Alzheimer's Disease Neuropathology Prevalence | Simoa p-Tau 217 Assay Enables Largest Population-Based Assessment (11,000+ Samples) Revealing Striking Age-Related Increase and Broad Treatment Eligibility
Quanterix Corporation(NASDAQ: QTRX),... ► Artikel lesen | |
| BELITE BIO | 129,00 | -0,77 % | Belite Bio, Inc: Belite Bio Announces China NMPA Agrees to New Drug Application with Priority Review based on Interim Analysis Results for the Treatment of Stargardt Disease with Tinlarebant | NMPA's response is based on the Phase 3 DRAGON interim analysis resultsTopline final data expected in Q4 2025 SAN DIEGO, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 28,970 | -1,63 % | Arcutis Biotherapeutics, Inc.: FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5 | Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026If approved, ZORYVE cream 0.3% would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children... ► Artikel lesen | |
| PROTAGONIST THERAPEUTICS | 88,78 | -0,07 % | Protagonist Therapeutics: Protagenic Therapeutics Announces Receipt of Nasdaq Non-Compliance Notice | NEW YORK, NY / ACCESS Newswire / November 27, 2025 / Protagenic Therapeutics, Inc. (Nasdaq:PTIX) (the "Company") today announced that it has received a notification letter from the Nasdaq Listing Qualifications... ► Artikel lesen | |
| TRAVERE THERAPEUTICS | 39,640 | -1,59 % | Why Travere Therapeutics Stock Popped by Nearly 14% on Wednesday | ||
| VERA THERAPEUTICS | 53,58 | -3,75 % | Vera Therapeutics Submits Biologics License Application to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgA Nephropathy | Atacicept received FDA Breakthrough Therapy Designation for the treatment of IgANORIGIN Phase 3 trial met its primary endpoint at the prespecified interim analysis of proteinuria reduction with 46%... ► Artikel lesen | |
| CELCUITY | 102,25 | -0,35 % | Celcuity Inc.: Celcuity Announces Completion of Submission of Its New Drug Application to the U.S. FDA for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer | MINNEAPOLIS, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the completion... ► Artikel lesen | |
| IMMUNOVANT | 26,160 | -2,68 % | Immunovant Inc.: Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients | First-ever potentially disease-modifying therapy for uncontrolled Graves' disease patientsOf 21 patients who entered the six-month off-treatment follow-up period, ~80% (17/21) demonstrated response... ► Artikel lesen | |
| COGENT BIOSCIENCES | 38,880 | -2,14 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) | -- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an objective response rate (CR+CRh+PR+CI) of 57% per mIWG criteria and 80% per PPR criteria -- -- Bezuclastinib... ► Artikel lesen |
LEXEO THERAPEUTICS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 10,240 Euro und damit -3,03 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LEXEO THERAPEUTICS INC finden Sie auf Wallstreet Online.